AliveCor Inc. is a global innovator and pioneer in transforming cardiac care using mobile technology. Based in California, USA, it is a global leader in AI-based compact ECG technology for point of care testing and remote patient monitoring.
AliveCor’s KardiaMobile & KardiaMobile 6L are US-FDA cleared to detect common arrhythmias like Atrial Fibrillation in just 30 seconds. These devices are medically validated and carry the confidence of over 170+ publications in peer-reviewed journals. KardiaMobile & Kardiamobile 6L are recommended by leading cardiologists and used by patients worldwide for accurate ECG recordings. KardiaMobile 6L is the world’s first and only US FDA cleared 6 lead personal ECG that provides a 6x better view of the heart. It provides multiple AI based automated ECG determinations including possible atrial fibrillation. The National Institute for Health and Care Excellence (NICE), UK recommends KardiaMobile 6L as a cost-effective way to detect Atrial Fibrillation.
Dr David Albert, the Chief Medical Officer of AliveCor, founded the company in 2011, along with scientists Bruce Satchwell and Kim Barne. In 2015, the company received multiple clearances from the FDA to offer algorithmic analysis of readings to determine various cardiac arrhythmias. AliveCor’s sole mission is to save lives and transform cardiology practice worldwide by offering healthcare professionals and patients intelligent, user-friendly, & personalized ECG device to monitor ECG test at home.
AliveCor has been recognised by FastCompany as 2018’s No. 1 most innovative company in artificial intelligence. AliveCor is a privately-held venture-backed company headquartered in Mountain View, California. For more details call us at 000 800 040 3846 or visit our site now.